Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply

Paul W Armstrong¹, Burkert Pieske², Christopher M O'Connor^{3

4}

Affiliations

Free article

Comment

Paul W Armstrong et al. Eur J Heart Fail. 2020 Oct.

Free article

. 2020 Oct;22(10):1935.

doi: 10.1002/ejhf.1765. Epub 2020 Feb 21.

Paul W Armstrong¹, Burkert Pieske², Christopher M O'Connor^{3

4}

No abstract available

Comment on

Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, Butler J, Ezekowitz J, Hernandez AF, Koglin J, Lam CSP, Ponikowski P, Roessig L, Voors AA, O'Connor CM, Armstrong PW; VICTORIA Study Group. Pieske B, et al. Eur J Heart Fail. 2019 Dec;21(12):1596-1604. doi: 10.1002/ejhf.1664. Epub 2019 Dec 9. Eur J Heart Fail. 2019. PMID: 31820546 Clinical Trial.
Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Letter regarding the article 'Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial'.
Aimo A, Castiglione V, Lombardi CM. Aimo A, et al. Eur J Heart Fail. 2020 Oct;22(10):1934-1935. doi: 10.1002/ejhf.1852. Epub 2020 Apr 30. Eur J Heart Fail. 2020. PMID: 32353173 No abstract available.